Major countries around the world are now inclined to allow biosimilars. The Indian biogenerics industry is poised to exploit the opportunity they did in the case of generics, although it has no clear advantage at the moment. "Natural advantage is created over time," says Arun Chandavarkar, CEO of Biocon. Industry leaders think that the right policies and investments can create an advantage over the next decade.
Industry Has Come a Long Way A biosimilar is a molecule that is close in structure and function to a biological drug. Small molecules are easy to make and characterise. Since the precise nature and function of biologicals are difficult to understand, it is hard to establish that two products are exactly the same. So, making a biosimilar is not as easy as making a generic small molecule, which is why we need to use a different measuring stick to estimate the potential of Indian i ..
Pharm.D @ SRIPMS-CBE-TN